Dermatology Drug Market Will Experience Modest Growth Of 8% Per Year Through 2008

With Enbrel, Amgen Becomes an Emerging Player in the Dermatology Drug Market, According to a New Report from Decision Resources

August 30, 2004--Waltham, Mass.--Decision Resources, Inc., one of the world’s leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the overall dermatology drug market (which includes atopic dermatitis, urticaria, and psoriasis) will experience modest growth of 8% per year through 2008. According to the new DR Pipeline Report entitled Dermatology Pipeline Analysis: A Market with Room to Grow, the psoriasis market will experience the most growth, with the atopic dermatitis market seeing more modest growth. The urticaria market will actually experience a decline.

The report also finds that Amgen will become a significant emerging player in the dermatological drug market with Enbrel for the treatment of adults with moderate-to-severe chronic plaque psoriasis.

< BACK